🇺🇸 FDA
Patent

US 6251396

Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein

expired A61KA61K38/00A61P

Quick answer

US patent 6251396 (Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein) held by Neurocrine Biosciences, Inc. expires Mon Jun 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time). Status: expired.

Key facts

Applicant
Neurocrine Biosciences, Inc.
Grant date
Tue Jun 26 2001 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
3
CPC classes
A61K, A61K38/00, A61P, A61P25/00, A61P25/28